DK2983663T3 - Langvarig frigivelse af bimatoprost, bimatoprost-analoger, prostamider og prostaglandiner til fedtreduktion - Google Patents

Langvarig frigivelse af bimatoprost, bimatoprost-analoger, prostamider og prostaglandiner til fedtreduktion Download PDF

Info

Publication number
DK2983663T3
DK2983663T3 DK14725582.2T DK14725582T DK2983663T3 DK 2983663 T3 DK2983663 T3 DK 2983663T3 DK 14725582 T DK14725582 T DK 14725582T DK 2983663 T3 DK2983663 T3 DK 2983663T3
Authority
DK
Denmark
Prior art keywords
bimatoprost
prostaglandines
prostamides
long
analogs
Prior art date
Application number
DK14725582.2T
Other languages
Danish (da)
English (en)
Inventor
Scott M Whitcup
Patrick M Hughes
David F Woodward
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK2983663T3 publication Critical patent/DK2983663T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts or implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
DK14725582.2T 2013-04-12 2014-04-09 Langvarig frigivelse af bimatoprost, bimatoprost-analoger, prostamider og prostaglandiner til fedtreduktion DK2983663T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361811682P 2013-04-12 2013-04-12
PCT/US2014/033558 WO2014169075A1 (en) 2013-04-12 2014-04-09 Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction

Publications (1)

Publication Number Publication Date
DK2983663T3 true DK2983663T3 (da) 2020-04-20

Family

ID=51686960

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14725582.2T DK2983663T3 (da) 2013-04-12 2014-04-09 Langvarig frigivelse af bimatoprost, bimatoprost-analoger, prostamider og prostaglandiner til fedtreduktion

Country Status (18)

Country Link
US (2) US20140308354A1 (https=)
EP (2) EP2983663B1 (https=)
JP (1) JP2016520561A (https=)
KR (1) KR20150141972A (https=)
CN (2) CN110840899A (https=)
AU (2) AU2014250937A1 (https=)
BR (1) BR112015025915A8 (https=)
CA (1) CA2908731A1 (https=)
CL (1) CL2015003023A1 (https=)
DK (1) DK2983663T3 (https=)
ES (1) ES2785382T3 (https=)
IL (1) IL242006B (https=)
MX (1) MX381097B (https=)
MY (1) MY187802A (https=)
RU (1) RU2015143859A (https=)
SG (2) SG10202109919PA (https=)
WO (1) WO2014169075A1 (https=)
ZA (1) ZA201507217B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176640A1 (en) * 2015-04-30 2016-11-03 Allergan, Inc. Cosmetic method and therapeutic use for fat reduction
US11452703B2 (en) * 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers
BR112023001073A2 (pt) * 2020-07-21 2023-03-07 Allergan Inc Implante intraocular com alto carregamento de prostamida
CN120731079A (zh) * 2023-04-18 2025-09-30 维乐菲尔概念有限公司 用于诱导黄体溶解的组合物和方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2218424A (en) * 1931-05-07 1940-10-15 Teleregister Corp Transmitter and code translator
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
US6124344A (en) 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
WO1996036599A1 (en) * 1995-05-18 1996-11-21 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension
NZ539582A (en) 2002-10-23 2007-07-27 Sucampo Ag Prostaglandin compounds for the treatment of obesity
CN101336887A (zh) * 2002-12-04 2009-01-07 参天制药株式会社 结膜下给药用药物组合物
JP2007515494A (ja) * 2003-12-22 2007-06-14 アベンティス・ファーマスーティカルズ・インコーポレイテツド 注射可能なフォスファチジルコリン調製物
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US7666912B2 (en) 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US9095506B2 (en) * 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US20130071349A1 (en) * 2010-03-02 2013-03-21 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
US20120022137A1 (en) 2010-07-21 2012-01-26 Rivers Hongwen M METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS
WO2014143754A2 (en) * 2013-03-15 2014-09-18 Allergan, Inc. Prostamide-containing intraocular implant
WO2016176640A1 (en) 2015-04-30 2016-11-03 Allergan, Inc. Cosmetic method and therapeutic use for fat reduction

Also Published As

Publication number Publication date
ES2785382T3 (es) 2020-10-06
EP2983663B1 (en) 2020-01-22
ZA201507217B (en) 2017-09-27
AU2019203214B2 (en) 2020-10-29
CN105101962A (zh) 2015-11-25
JP2016520561A (ja) 2016-07-14
WO2014169075A1 (en) 2014-10-16
RU2015143859A (ru) 2017-05-16
CL2015003023A1 (es) 2016-06-10
RU2015143859A3 (https=) 2018-03-05
CA2908731A1 (en) 2014-10-16
BR112015025915A8 (pt) 2020-01-14
KR20150141972A (ko) 2015-12-21
SG10202109919PA (en) 2021-10-28
HK1221406A1 (en) 2017-06-02
IL242006B (en) 2020-04-30
BR112015025915A2 (pt) 2017-07-25
SG10201701938PA (en) 2017-04-27
US10682361B2 (en) 2020-06-16
MY187802A (en) 2021-10-26
US20160339039A1 (en) 2016-11-24
MX2015014320A (es) 2015-12-08
CN110840899A (zh) 2020-02-28
NZ712804A (en) 2021-02-26
MX381097B (es) 2025-03-12
US20140308354A1 (en) 2014-10-16
AU2014250937A1 (en) 2015-10-22
EP3656375A1 (en) 2020-05-27
EP2983663A1 (en) 2016-02-17
AU2019203214A1 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
DK2986004T3 (da) Fremgangsmåde til entropiafkodning af skivesegmenter
IL253627B (en) Predicting t cell epitopes useful for vaccination
DK3611262T3 (da) Fremgangsmåder til sekvensering af immunrepertoire
DK3689853T3 (da) Fremgangsmåde til syntese af thyreoideahormonanaloger og polymorfer deraf
DK2968529T3 (da) Fremstilling af jordnøddeformuleringer til oral desensibilisering
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
HUE050430T2 (hu) Fekális mikrobióta mintavételezési eljárás
DK3556869T3 (da) Sammensætninger og fremgangsmåder til sekventering af polynukleotider
DK2972353T3 (da) Forbedrede fremgangsmåder til udførelse af multipleksanalyser
DK3160470T3 (da) Analoger af pridopidin, fremstilling og anvendelse heraf
HUE057403T2 (hu) Transzdukciós puffer
HUE043088T2 (hu) Halikondrin B analógok szintézisében alkalmazható eljárások
DK2968673T3 (da) Fremgangsmåde til decellularisering af vævstransplantater
DK2968269T3 (da) Fremgangsmåde til fremstilling af beta-3-agonister og mellemprodukter
DK3689380T3 (da) Bløde kapsler af calcifediol
DK2992104T3 (da) Fremgangsmåde til ekspression
DK2962754T3 (da) Fremgangsmåde til fremstilling af co-shiftkatalysator
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK3569166T3 (da) Indretning til akut behandling af hjertestop
HRP20181596T1 (hr) Tiazolopirimidinoni kao modulatori aktivnosti nmda receptora
DK3038656T3 (da) Forbindelse af glycosaminoglycan, fremgangsmåde til fremstilling og anvendelse deraf
DK3525672T3 (da) Grænseflade til åndedrætsprøvetagning
DK3369724T3 (da) Fremgangsmåde til fremstilling af iopamidol
DK3387232T3 (da) Forbedrede rammeelementer til opbevaring af monolitter
DK3374495T3 (da) Forbedrede fremgangsmåder til vævsfremstilling